Tetrahydrocurcumin for Health & Longevity

Evidence Review created on 10/21/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: THC, THU, THCu, TC, Tetrahydrodiferuloylmethane, Tetrahydrocurcuminoids, Curcumin C3 Reduct, C3 Reduct

Motivation

Tetrahydrocurcumin is a colorless compound that the body makes from curcumin, the yellow pigment of turmeric, and that manufacturers now produce directly by chemically converting curcumin. It is sold as a dietary supplement on the premise that it is more stable and better absorbed than curcumin, and so may deliver curcumin’s proposed effects on inflammation and cell damage more reliably. Its main proposed action is to calm inflammation and chemical stress inside cells.

Interest from the longevity community grew out of animal studies that tested its effect on lifespan, and out of a long-running question in turmeric research: whether curcumin’s effects in the body are actually carried by its breakdown products. Human research is sparse, consisting of a few small studies, one of them run by the main manufacturer, plus a European food-safety assessment, built largely on manufacturer-supplied safety data, that set a daily intake limit.

This review examines what is known about tetrahydrocurcumin’s benefits, risks, interactions and practical use for health-focused adults, how much of that knowledge is borrowed from curcumin, animal work or manufacturer-funded studies, and where the largest gaps remain.

Benefits - Risks - Protocol - Conclusion

The items below give a high-level overview of tetrahydrocurcumin, its lifespan data in animals and how it differs from curcumin.

No content discussing tetrahydrocurcumin in depth was found from the priority experts. Life Extension mentions tetrahydrocurcumin only in passing, in a sentence or two within broader pages such as a curcumin lifespan newsletter and its Caloric Restriction protocol, too briefly to list; Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io returned either no matches or material on curcumin and turmeric only.

Grokipedia

No Grokipedia article dedicated to tetrahydrocurcumin exists; the site’s search returns only pages on individual studies and products and the broader curcuminoid and curcumin entries.

Examine

No Examine article on tetrahydrocurcumin exists; the site’s search returns no results for the term.

ConsumerLab

No ConsumerLab article on tetrahydrocurcumin exists; the site’s search returns no results for the term.

Systematic Reviews

The only systematic review that addresses tetrahydrocurcumin itself is listed below.

No systematic review or meta-analysis addresses tetrahydrocurcumin’s risks or safety, so the risk side of the trade-off is unrepresented in this section.

Mechanism of Action

Tetrahydrocurcumin is curcumin with hydrogen added across its central carbon–carbon double bonds. This makes it colorless and more stable at body pH (Pan et al., 1999), but removes the reactive group through which curcumin binds many proteins.

  • Antioxidant and anti-inflammatory signaling: In cell and animal studies it neutralizes free radicals and lowers inflammatory messengers via NF-κB (a master switch for inflammatory genes) and MAPK (stress-signaling enzymes) (review by Zhou et al., 2024).
  • Longevity pathways: In flies, lifespan extension required FOXO (stress-resistance gene switches) and Sir2 (a sirtuin “longevity” enzyme) (Xiang et al., 2011); in cells it dampens PI3K/Akt/mTOR (a growth-signaling chain that suppresses autophagy, the cell’s recycling process) (Wu et al., 2011, co-authored by main manufacturer Sabinsa).
  • Competing view: It is weaker than curcumin against COX-2 (an inflammation enzyme) (Ireson et al., 2001), did not inhibit HDAC1 (an enzyme that tightens DNA packaging) (Novaes et al., 2017, manufacturer co-authored) and did not reduce amyloid plaques in mice (Begum et al., 2008).
  • Absorption and elimination: No human half-life is published. In rats absorption peaked near 1 hour, was low, showed later secondary peaks and was mainly non-renal in excretion (Novaes et al., 2017). UGT enzymes (liver enzymes that tag compounds for excretion), including UGT2B7, process it more slowly than curcumin (Guo et al., 2024). In mice it reached far higher blood levels than curcumin but similar brain levels (Begum et al., 2008).
  • Selectivity: It has no single target and acts on many pathways at relatively high concentrations.

Historical Context & Evolution

Turmeric (Curcuma longa) has been used for millennia as a spice and in Ayurvedic and Chinese medicine, and curcumin is its main pigment. Tetrahydrocurcumin entered science as a product of curcumin metabolism: a 1978 rat study found it among the main curcumin metabolites in bile (Holder et al., 1978), and a 1999 mouse study confirmed it as a major metabolite far more stable than curcumin in solution (Pan et al., 1999). Japanese researchers studying dietary antioxidants also reported it as the strongest antioxidant among curcumin’s metabolites and tested it in kidney-damage and diabetes models (review by Osawa, 2007).

Because it is colorless, it also drew cosmetic interest as a skin ingredient free of curcumin’s yellow stain, and creams containing it were patch-tested on volunteers (Wattanakrai et al., 2007). Interest for longevity followed two animal findings: a mouse study in which it lengthened average lifespan only when started in middle age (Kitani et al., 2007), and a fruit-fly study linking its effect to conserved longevity genes (Xiang et al., 2011).

Opinion has since shifted in both directions. Early work framed it as the “active form” of curcumin, while comparative studies showed it is weaker at some curcumin actions (Ireson et al., 2001; Begum et al., 2008). Regulatory review then arrived: the European Food Safety Authority (EFSA) assessed a manufacturer’s product in 2021 (EFSA, 2021), leading to EU authorization as a novel food supplement in 2022 (Commission Implementing Regulation (EU) 2022/961). Human outcome trials remain few.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence for tetrahydrocurcumin consists of one uncontrolled study and two small randomized pilot trials, none replicated by an independent research group.

Medium 🟩 🟩

No benefit reaches Medium: no controlled human trial of oral tetrahydrocurcumin alone has shown an improvement in a clinical endpoint on its primary outcome.

Low 🟩

Canker Sore and Gingivitis Symptom Relief ⭕️ Not Central to Health & Longevity

In an uncontrolled study run by Sabinsa, the main manufacturer, 60 adults chewing 100 mg tetrahydrocurcuminoid tablets twice daily for 21 days had less mouth-ulcer pain and gum inflammation (Majeed et al., 2020). Canker sores often heal unaided within two weeks. This bears on oral comfort, not longevity.

Magnitude: Mean gingival index total (a dentist-scored rating of gum appearance, bleeding and inflammation) fell from 2.10 to 0.38 points and median canker-sore pain score from 3 to 0 by day 21 (no control group).

Depressive Symptoms as an Add-On to Escitalopram ⚠️ Conflicted

In a randomized unblinded pilot of 19 adults with major depression, adding 200 mg/day to escitalopram for 29 days left total depression scores unchanged versus escitalopram alone; one digestive item improved (Guo et al., 2025). It was tested only with an antidepressant. Net reading: no measurable added antidepressant effect.

Magnitude: Final HAMD-17 (17-item Hamilton Depression Rating Scale) score 2.13 points higher with the add-on than with escitalopram alone (12.88 vs 10.75; the add-on group started 2.50 points higher, 21.38 vs 18.88), not significantly different (p = 0.25; the p-value is the probability of a difference this large arising by chance); gastrointestinal item median change −0.5 vs 0.0 points (p = 0.025).

Joint Pain (Extrapolated from Curcumin Trials)

Meta-analysis of turmeric and curcumin trials reports less arthritis pain than placebo (Daily et al., 2016); its lead author is affiliated with a supplement manufacturer. Tetrahydrocurcumin reduced osteoarthritis-like symptoms in estrogen-deficient rats (Park et al., 2016). Evidence is indirect: no human joint trial tested tetrahydrocurcumin itself.

Magnitude: In curcumin trials, pain visual analogue score (a 0–10 pain rating line) 2.04 points lower than placebo (95% CI, the range likely to contain the true effect, −2.85 to −1.24; 3 trials); tetrahydrocurcumin itself is untested in human joints.

Vitiligo Repigmentation (Topical, with Phototherapy) ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In a randomized within-patient trial in 10 people with vitiligo (patchy pigment loss), tetrahydrocurcuminoid cream plus ultraviolet B light repigmented patches slightly, not significantly, more than light alone (Asawanonda & Klahan, 2010). It bears on skin pigmentation, not longevity; topical use differs from oral. Net reading: no demonstrated added benefit.

Magnitude: The direction favored the combination at 8 and 12 weeks without statistical significance (p = 0.078 and 0.158); the literature reports no outcome figure for the between-treatment difference.

Speculative 🟨

Lifespan Extension

Mice started at 13 months lived 11.7% longer on average, but not when started at 19 months (Kitani et al., 2007); flies also lived longer (Xiang et al., 2011). Animal data only.

Blood Pressure, Vascular and Kidney Protection

In rodents it lowered blood pressure, arterial stiffness, urine protein loss and kidney scarring after cadmium exposure or partial kidney removal (Sangartit et al., 2014; Lau et al., 2018). Animal data only.

Blood Sugar and Lipid Regulation

It normalized blood glucose in diabetic rats (Pari & Murugan, 2005); a systematic review of curcumin metabolites describes preclinical glucose and lipid effects (Liu et al., 2026). No human data.

Liver Fat and Liver Protection

In high-fat-fed rats it reduced liver fat, inflammation and oxidative stress by restoring liver cells’ breakdown of stored fat (Wu et al., 2024). No human data exist; basis is animal and cell only.

Brain Inflammation and Cognitive Aging

In Alzheimer’s-model mice it reduced brain inflammation and soluble amyloid but, unlike curcumin, not plaques (Begum et al., 2008). No human cognitive data exist; basis is animal only.

Cancer Prevention

Cell and animal studies report reduced tumor growth and spread through several pathways (review by Lai et al., 2020). No human cancer data exist, and effects at supplement doses are unknown.

Skin Photoaging Protection

Tetrahydrocurcumin given daily at 100 mg/kg body weight reduced wrinkling and skin thickening in ultraviolet-exposed mice (Xu et al., 2022). No controlled human photoaging data exist; basis is animal only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study links any gene variant to response. Variation in UGT enzymes and in gut bacteria that reduce curcumin (Luo et al., 2024) could plausibly alter exposure, but this is untested.
  • Baseline biomarkers: No trial has stratified response by baseline inflammation, glucose or lipids; the animal benefits were seen in models with induced disease, which suggests larger effects where those markers are already abnormal.
  • Sex: Mouse lifespan data come from males only (Kitani et al., 2007); the fly lifespan effect occurred in both sexes (Xiang et al., 2011). The oral-health study enrolled mostly men (49 of 60) (Majeed et al., 2020), so human sex differences are unknown.
  • Pre-existing conditions: Signals come from people with mouth ulcers, gingivitis or major depression and from diseased animal models; whether healthy adults gain anything is unstudied.
  • Age: The mouse lifespan gain appeared when treatment began in middle age (13 months) but not late in life (19 months) (Kitani et al., 2007), suggesting any benefit may depend on starting earlier.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: of the two small controlled human trials of tetrahydrocurcumin, the topical vitiligo study reported only minor, well-tolerated adverse effects (Asawanonda & Klahan, 2010) and the oral depression pilot reported no adverse-event data in its full text, although its abstract calls the add-on safe (Guo et al., 2025), and the harm signals below come from curcumin and turmeric products or from animal and laboratory work.

Medium 🟥 🟥

No risk reaches Medium: the direct human harm data for tetrahydrocurcumin are one uncontrolled oral study reporting no adverse events (Majeed et al., 2020), one small topical trial reporting only minor adverse effects (Asawanonda & Klahan, 2010) and a skin-allergy case report (Lamb & Wilkinson, 2003), and the class signals rest on related turmeric compounds rather than tetrahydrocurcumin.

Low 🟥

Drug-Induced Liver Injury (Turmeric Class Signal)

Rare, sometimes severe hepatitis is linked to turmeric supplements, typically after 1–4 months and strongly tied to HLA-B*35:01 (a variant of an immune gene that displays protein fragments to immune cells) (Halegoua-DeMarzio et al., 2023). No case with tetrahydrocurcumin is reported, so evidence is indirect.

Magnitude: 10 turmeric cases in the US Drug-Induced Liver Injury Network (DILIN) registry (2004–2022): 5 hospitalized, 1 death; 7 of 10 carried HLA-B*35:01 (allele frequency, the share of gene copies carrying the variant, 0.45 vs 0.056–0.069 in population controls); case series (no control group), so incidence cannot be estimated.

Minor Gastrointestinal and General Complaints (Curcumin Data)

In a single-dose curcumin escalation study (500–12,000 mg, Sabinsa product), 7 of 24 healthy volunteers had mild adverse events unrelated to dose (Lao et al., 2006). The tetrahydrocurcumin oral-health study reported none (Majeed et al., 2020). Evidence is indirect.

Magnitude: 7 of 24 participants (30%) had grade 1 (mild) adverse events (no control group); the source has no comparison group.

Allergic Contact Dermatitis (Topical Use)

Contact allergy to tetrahydrocurcumin (an immune skin rash where the compound touches the skin) has been documented in a case report (Lamb & Wilkinson, 2003). It concerns skin products, not oral supplements, so evidence for oral use is indirect.

Magnitude: Not quantified in available studies. Only a case report exists, so no rate can be estimated.

Gallbladder Contraction (Curcumin Class Signal)

In a randomized, double-blind ultrasound study in which 12 healthy volunteers took both curcumin and placebo, a single 20 mg curcumin dose contracted the gallbladder significantly more than placebo (Rasyid & Lelo, 1999), a concern with gallstones or bile-duct obstruction. No tetrahydrocurcumin data exist, so evidence is indirect (curcumin only).

Magnitude: Gallbladder volume fell 29.3% (±8.3%) 2 hours after curcumin, reported as significantly more than after placebo; the source gives no placebo figure, so no between-group difference is stated.

Speculative 🟨

Increased Bleeding Tendency

It blocked human platelet activation in the lab and clot growth in mice, without prolonging mouse bleeding time (Li et al., 2022). No human bleeding data; basis is mechanistic and animal.

Altered Levels of Other Medications

In lab assays it inhibited CYP2C9 and CYP3A4 (liver enzymes that break down many drugs) (Novaes et al., 2017) and ABCB1 (a drug-expelling cell pump) (Limtrakul et al., 2007). Basis is laboratory only.

Reproductive and Developmental Effects ⚠️ Conflicted

Sabinsa’s rat reproduction test reported no harm up to 400 mg/kg (Majeed et al., 2019); EFSA set the no-adverse-effect level at 200 mg/kg (EFSA, 2021). Net reading: animal-only; harm above 200 mg/kg possible.

Low Blood Sugar with Diabetes Medication

Glucose lowering in diabetic rats (Pari & Murugan, 2005) suggests possible additive effects with glucose-lowering drugs. No human data exist; basis is animal only.

Risk-Modifying Factors

  • Genetic polymorphisms: Carriers of HLA-B*35:01 were heavily over-represented among turmeric liver-injury cases (Halegoua-DeMarzio et al., 2023); whether this applies to tetrahydrocurcumin is unknown. Reduced-function UGT variants could theoretically raise exposure.
  • Baseline biomarkers: Elevated liver enzymes (ALT, alanine aminotransferase; AST, aspartate aminotransferase) before starting make new liver injury harder to detect and may signal vulnerability; a raised INR (international normalized ratio, a clotting-time measure) adds to theoretical bleeding concerns.
  • Sex: Eight of ten turmeric liver-injury cases were women (Halegoua-DeMarzio et al., 2023); no sex-specific safety data exist for tetrahydrocurcumin itself.
  • Pre-existing conditions: Liver disease, gallstones, bleeding disorders, diabetes treated with glucose-lowering drugs, and pregnancy or breastfeeding (excluded by the EU authorization) raise concern; data in these groups are absent.
  • Age: Older adults more often take anticoagulants (blood-thinning medicines) and many medications, raising interaction risk; the EU safe level was set for adults generally, without age-specific data (EFSA, 2021).

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs (clot-preventing medicines: warfarin, apixaban, rivaroxaban, clopidogrel): Caution (theoretical). Platelet inhibition in lab and mouse studies could add to bleeding risk; in mice it did not strengthen aspirin’s effect (Li et al., 2022). INR checks after starting apply to warfarin users.
  • Drugs cleared by CYP2C9 (warfarin, phenytoin, glipizide, celecoxib): Monitor (theoretical). Laboratory CYP2C9 inhibition (Novaes et al., 2017) could raise drug levels and effects; INR, glucose or drug-level checks after starting address this.
  • Drugs cleared by CYP3A4 or ABCB1 (tacrolimus, cyclosporine, simvastatin, digoxin): Caution (theoretical). Laboratory inhibition of CYP3A4 (Novaes et al., 2017) and the ABCB1 pump (Limtrakul et al., 2007) could raise levels of narrow-margin drugs; drug-level checks after starting address this.
  • Glucose-lowering drugs (insulin, glipizide, glimepiride, metformin): Monitor (theoretical). Animal glucose lowering (Pari & Murugan, 2005) suggests additive hypoglycemia (low blood sugar); more frequent glucose checks initially address this.
  • Chemotherapy (docetaxel, doxorubicin, paclitaxel, vinblastine): Avoid (theoretical) unless the oncologist agrees. Efflux-pump inhibition (Limtrakul et al., 2007) and antioxidant activity could alter drug exposure or effect.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen) and aspirin: Caution (theoretical). Additive platelet inhibition may increase bruising or gastrointestinal bleeding; avoiding regular high-dose combined use limits this.
  • Other curcumin or turmeric supplements: Avoid on the same day. The EU authorization requires labels to state this (Commission Implementing Regulation (EU) 2022/961), since combined intake could narrow the safety margin EFSA assessed.
  • Piperine (black pepper extract): Caution (theoretical). It inhibits drug-metabolizing enzymes, possibly raising levels of other medicines, and appeared in 3 of 7 tested products in turmeric liver-injury cases (Halegoua-DeMarzio et al., 2023), suggesting added liver risk; piperine-free products avoid both.
  • Additive antiplatelet supplements (fish oil, ginkgo, garlic extract, high-dose vitamin E): Caution (theoretical). Combined platelet effects may increase bleeding tendency; pausing both 1–2 weeks before surgery limits this.
  • Additive glucose-lowering supplements (berberine, alpha-lipoic acid, chromium): Monitor (theoretical). Stacking may lower glucose further in people on diabetes medication, risking hypoglycemia; more frequent glucose checks initially address this.
  • Surgery and dental procedures: Caution (theoretical). Pausing 1–2 weeks beforehand is common practice to limit possible bleeding from platelet effects.

Populations who should avoid Tetrahydrocurcumin:

  • Pregnant or breastfeeding women, and anyone under adult age (the EU authorization is limited to adults, excluding pregnant and lactating women) (Commission Implementing Regulation (EU) 2022/961)
  • People with prior turmeric- or curcumin-associated liver injury, or a history of liver problems without medical supervision, per the United States Pharmacopeia (USP), a nonprofit standards body that does not sell turmeric products (Akhtar et al., 2026)
  • People with bleeding disorders or scheduled surgery (theoretical)
  • People with gallstones or bile-duct obstruction (theoretical)
  • People receiving chemotherapy without oncologist approval (theoretical)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Intake within the assessed safe level: Intake at or below 140 mg/day, the level EFSA judged safe for adults (EFSA, 2021), limits unknown long-term toxicity.
  • No stacking of curcuminoids: Not combining with turmeric or curcumin supplements on the same day, as the EU label requires (Commission Implementing Regulation (EU) 2022/961), protects the assessed safety margin.
  • Liver monitoring: Testing ALT and AST at baseline and again at 1–3 months, matching the usual 1–4 month latency of turmeric liver injury (Halegoua-DeMarzio et al., 2023), catches hepatitis early.
  • Stopping on liver symptoms: Per USP (no revenue stake), use stops at abdominal pain, dark urine or jaundice (yellowing skin or eyes) (Akhtar et al., 2026), preventing progressive liver injury; rising ALT on monitoring prompts medical review.
  • Pre-surgery pause: Stopping 1–2 weeks before procedures reduces possible bleeding from platelet inhibition.
  • INR checks with warfarin: An INR recheck within 1–2 weeks of starting or stopping catches a possible rise in bleeding risk.
  • Glucose checks with diabetes drugs: More frequent home glucose checks during the first 2–4 weeks detect hypoglycemia early.
  • Piperine-free products: Formulas without black pepper extract reduce interaction and liver-injury concerns.

Therapeutic Protocol

Timing, splitting and titration steps below without a citation reflect common practice; doses are cited to their sources.

  • Regulatory dose ceiling: 140 mg/day of tetrahydrocurcuminoids for adults, the EU-authorized maximum in food supplements (Commission Implementing Regulation (EU) 2022/961), based on the EFSA safe level (EFSA, 2021).
  • Manufacturer-proposed and trial doses: Sabinsa proposed 300 mg/day (EFSA, 2021); trials used 100 mg twice daily (Majeed et al., 2020) and 200 mg/day (Guo et al., 2025), both above the EU ceiling.
  • Competing approaches: Integrative practitioners and the manufacturer present it as a better-absorbed curcumin alternative; conventional medicine has no indication for it. No longevity clinician has published a protocol; Sabinsa (Curcumin C3 Reduct) popularized the ingredient.
  • Time of day: No study compares timing; taking it with a fat-containing meal is common practice because it is fat-soluble.
  • Half-life: No human half-life is published; in rats blood levels peaked at about 1 hour, with later secondary peaks (Novaes et al., 2017).
  • Single vs split dose: Given the short early peak, splitting into two doses, as in the oral-health trial (Majeed et al., 2020), is common practice.
  • Genetic polymorphisms: No pharmacogenetic dosing data exist. HLA-B*35:01 carriers, if known, may weigh the turmeric liver-injury link (Halegoua-DeMarzio et al., 2023) before use.
  • Sex: No sex-specific dosing data exist; the oral-health study enrolled mostly men (Majeed et al., 2020) and the depression trial mostly women (Guo et al., 2025).
  • Age: In mice benefit appeared only when started in middle age (Kitani et al., 2007); older adults taking several medications face more interaction risk, which a medication review addresses.
  • Baseline biomarkers: Normal baseline ALT and AST support starting; no biomarker predicts response.
  • Pre-existing conditions: Liver disease, bleeding disorders and medication-treated diabetes are settings where clinician oversight is common practice.

Discontinuation & Cycling

  • Duration: No study defines short-term versus lifelong use; oral trials lasted 3–4 weeks (Majeed et al., 2020; Guo et al., 2025), a topical trial 12 weeks (Asawanonda & Klahan, 2010); longer-term human safety is unstudied.
  • Withdrawal effects: None are known or expected; no dependence or rebound has been described.
  • Tapering: Not needed; it can be stopped abruptly, including before surgery or at signs of liver injury.
  • Cycling: No evidence shows that cycling maintains efficacy; some users cycle (for example 8 weeks on, 2–4 weeks off) as common practice, mainly to limit cumulative exposure.

Sourcing and Quality

  • Form and purity: The EU specification requires more than 95% tetrahydrocurcuminoids and caps palladium catalyst residue below 5 mg/kg (Commission Implementing Regulation (EU) 2022/961).
  • Color check: Pure tetrahydrocurcumin is white to pale yellow (EFSA, 2021); a strongly yellow powder suggests residual curcumin rather than the hydrogenated compound.
  • Third-party testing: Independent verification (USP Verified or NSF Certified) and a certificate of analysis covering identity, heavy metals and microbial limits indicate higher quality.
  • Branded ingredient: Most products use Sabinsa’s Curcumin C3 Reduct; in the EU only Sabinsa may market it until July 2027 (Regulation (EU) 2022/961). The depression trial used a Swanson product (Guo et al., 2025).
  • Avoid complex blends: Single-ingredient products make dose tracking easier and avoid hidden curcumin or piperine that would breach the stacking restriction.
  • Topical vs oral: Many products are skin creams; these do not deliver an oral dose and do not count as supplementation.

Practical Considerations

  • Time to effect: Oral-health (Majeed et al., 2020) and depression (Guo et al., 2025) trials assessed effects after 2–4 weeks; any longevity effect, if real, would take years and has never been measured in people.
  • Common pitfalls: Assuming better absorption means better outcomes; exceeding 140 mg/day; stacking with turmeric products; and confusing “THC” on labels with the cannabis compound tetrahydrocannabinol.
  • Regulatory status (EU): Authorized in 2022 as a novel food for adult food supplements at up to 140 mg/day, with mandatory warnings (Commission Implementing Regulation (EU) 2022/961).
  • Regulatory status (US): Sold as a dietary supplement; manufacturers, not FDA (the US Food and Drug Administration), evaluate safety before marketing, and FDA acts after products reach the market (FDA Dietary Supplements).
  • Cost and access: Widely available online at modest cost; not exceptionally expensive or hard to obtain.

Interaction with Foundational Habits

  • Sleep: No direct interaction known. In the depression trial, insomnia items did not differ between groups (Guo et al., 2025); no study has measured sleep quality as an outcome. Taking it with the evening meal is unlikely to disturb sleep.
  • Nutrition: Potentiating with dietary fat, which aids absorption of fat-soluble compounds (common practice). Culinary turmeric contributes curcumin that the body partly converts to tetrahydrocurcumin; normal food use is not covered by the EU same-day supplement warning (Regulation (EU) 2022/961).
  • Exercise: Unknown, possibly blunting. High-dose vitamins C and E blunted exercise-induced insulin-sensitivity gains (Ristow et al., 2009); no tetrahydrocurcumin data exist. Taking it away from the workout window is a cautious option.
  • Stress management: Indirect. It reversed depression-like behavior in chronically stressed mice, but in people with depression the anxiety items did not differ from antidepressant alone (Guo et al., 2025); no cortisol data exist.

Monitoring Protocol & Defining Success

Before starting, baseline testing covers liver enzymes and bilirubin, because turmeric-class liver injury is the main human harm signal, plus a clotting test for anyone on warfarin and fasting glucose for anyone on glucose-lowering drugs. An optional hs-CRP (high-sensitivity C-reactive protein, a blood marker of inflammation) gives a personal reference point, since tetrahydrocurcumin is proposed to reduce inflammation, although no human study has measured this.

Ongoing monitoring follows this cadence: liver enzymes at 4–6 weeks and again at 3 months, then every 6–12 months while use continues. Warfarin users recheck clotting within 1–2 weeks of starting or stopping. People on diabetes medication check glucose at home more often during the first month. Any jaundice, dark urine or abdominal pain prompts immediate testing regardless of schedule. Success is defined as unchanged safety markers plus the personal outcome being tracked.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 7–56 U/L (standard reference range) Safety check: rise stops use Liver-injury screen; turmeric injury mostly damages liver cells directly (Halegoua-DeMarzio et al., 2023); no fasting needed; pair with AST
AST 10–40 U/L (standard reference range) Safety check: rise stops use Pair with ALT; recent strenuous exercise can raise AST, so avoid hard training 48 hours before testing
Total bilirubin 0.1–1.2 mg/dL (standard reference range) Safety check: rise stops use Marker of more serious liver injury; Gilbert syndrome (a harmless inherited bilirubin rise) can elevate it at baseline
INR (warfarin users only) No established target for supplement use; track against the prescriber’s individual range Safety check: rise changes use Interaction is theoretical; recheck 1–2 weeks after starting or stopping
Fasting glucose (users of glucose-lowering drugs) 70–99 mg/dL (standard reference range) Safety check: low values change use Animal data suggest glucose lowering; morning fasting sample; pair with home readings
hs-CRP No established target; track change from own baseline Expected to change (proposed anti-inflammatory effect, unproven in humans) Measure when free of acute illness; repeat at 3 months; a single value is noisy

Qualitative markers to track:

  • Oral comfort, including gum bleeding and mouth-ulcer frequency
  • Joint comfort and morning stiffness
  • Digestive tolerance (bloating, stool changes)
  • Mood and energy
  • Early signs of liver injury: fatigue, itching, dark urine, yellow eyes
  • Unusual bruising or bleeding

Emerging Research

  • No registered trials: A ClinicalTrials.gov registry search for tetrahydrocurcumin found no registered trial using it as an intervention as of 21 October 2026 (the three hits test turmeric or curcumin products), so no ongoing registered human study is positioned to change the current picture soon.
  • Mammalian lifespan test: Curcumin had no lifespan effect in the National Institute on Aging Interventions Testing Program (Strong et al., 2013); a comparable multi-site test of tetrahydrocurcumin has not been reported. A positive result would strengthen, a null weaken, the longevity case.
  • Depression augmentation: The unblinded pilot found no total-score benefit (Guo et al., 2025); a blinded, placebo-controlled trial would settle whether the digestive-symptom signal is real.
  • Kidney disease: In a 2026 rat study tetrahydrocurcumin reduced urine protein loss and scarring-related genes but did not improve serum creatinine (a kidney-filtration marker) (Alvarez et al., 2026), a mixed signal for future human kidney trials.
  • Platelets and diabetes: In diabetic mice it reduced platelet hyperreactivity more than curcumin (Hu et al., 2026); this could support a cardiovascular benefit but also sharpens the bleeding question.
  • Liver safety genetics: Further work on HLA-B*35:01 and turmeric liver injury (Halegoua-DeMarzio et al., 2023) could show whether tetrahydrocurcumin shares this risk, which would weaken its safety case.
  • Human absorption and elimination: The only human study of the purified product in the EFSA dossier is unpublished, and EFSA reports no human absorption data (EFSA, 2021); published human half-life and dose-exposure data are a prerequisite for rational dosing.

Conclusion

Tetrahydrocurcumin is a colorless form of curcumin, made by the body and now manufactured directly, that is marketed as a more stable, better-absorbed way to obtain turmeric’s proposed benefits. For health-focused adults willing to experiment, the central fact is that almost all of its appeal rests on animal and laboratory studies. In mice and flies it extended lifespan, and in rodents it protected blood vessels, kidneys, liver, blood sugar control and brain tissue, but none of these effects has been tested in people.

The human evidence is thin and mixed. A small study without a comparison group suggested relief of mouth ulcers and gum inflammation, while small studies that did use comparison groups found no clear added benefit for depression or for a skin-pigment disorder treated with light. Some of curcumin’s actions also appear weaker or absent in this form, so evidence for curcumin does not automatically transfer.

Safety looks reassuring at modest doses in animal testing, and a European food-safety review set a daily limit for adults that is lower than the amounts used in trials. Rare liver injury linked to turmeric products, possible effects on bleeding and on how the body handles other medicines, and the absence of long-term human data remain open concerns.

Much of the human and safety evidence comes from the main manufacturer, a conflict of interest that colors the record; the regulators and standards bodies cited have no revenue stake in their conclusions. Overall, tetrahydrocurcumin is a plausible but largely untested longevity candidate.

Top - Benefits - Risks - Protocol